GTG Further Expands Its Licensing Program in Europe

Genetic Technologies Limited ("GTG") (NASDAQ:GENE)
(ASX:GTG) is pleased to announce that it has now appointed the law
firm of Doralt Seist Csoklich to help further expand the GTG licensing
program in Europe. This firm, based in Vienna, Austria will especially
focus on new licensing opportunities in the German speaking countries
of Germany, Austria and Switzerland.
   This appointment follows similar recent announcements concerning
the appointment of PatentBridge LLC on the U.S. west coast, Dickstein
Shapiro Morin & Oshinsky LLP on the U.S. east coast and SJ Berwin in
London.
   This latest appointment follows market research by GTG which
identified a significant number of biotechnology firms based in
Germany, Austria and Switzerland, who would benefit from taking a
license to the GTG non-coding patents.
   About the GTG non-coding patents. The GTG non-coding patents are
relevant to the current and intended activities of many biotechnology
companies and research teams world-wide. The patents fall into two
families -- non-coding analysis and non-coding mapping, and the
patents are issued in all 24 countries in which they were originally
filed. GTG has successfully settled six legal challenges to the
patents on terms favourable to GTG, and GTG is now focussed on
maximizing its licensing opportunities during the next 10 years,
before these patents expire. GTG has so far approved 31 licenses to
these patents, 26 of them to commercial entities, for a total
consideration of approximately A$53 million. GTG has meanwhile
identified numerous additional parties who would benefit from a
license to the GTG non-coding patents. Accordingly, GTG continues to
apply increasing resources to this global out-licensing program.
   About Doralt Seist Csoklich. This firm provides legal counselling
across a wide range of business activities, including trans-border
transactions. One partner, Dr. Christoph Leitgeb, has both a legal
degree and also a PhD in molecular genetics, and with his extensive
experience in patent law and licensing, is expected to take an active
role in assisting the GTG licensing program in the German speaking
countries.

   About Genetic Technologies Limited

   Genetic Technologies was an early pioneer in recognizing important
new applications for "non-coding" DNA (DeoxyriboNucleic Acid). The
Company has since been granted patents in 24 countries around the
world, securing intellectual property rights for particular uses of
non-coding DNA in genetic analysis and gene mapping across all genes
in all multicellular species. Its three-pronged business strategy
includes: 1) the global commercialization of its patents through an
active licensing program; 2) the expansion of its dominant commercial
genetic testing business in Australia; and, 3) the commercialization
of its various research and development projects aimed at generating
further intellectual property of global commercial significance.

   This announcement may contain forward-looking statements within
the meaning of Section 27A of the U.S. Securities Act of 1933 and
Section 21E of the U.S. Securities Exchange Act of 1934 with respect
to the financial condition, results and business
achievements/performance of Genetic Technologies Limited and certain
of the plans and objectives of its management. These statements are
statements that are not historical facts. Words such as "should",
"expects", "anticipates", "estimates", "believes" or similar
expressions, as they relate to Genetic Technologies Limited, are
intended to identify forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they
reflect Genetic Technologies' current expectations and assumptions as
to future events and circumstances that may not prove accurate. There
is no guarantee that the expected events, trends or results will
actually occur. Any changes in such assumptions or expectations could
cause actual results to differ materially from current expectations.